SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syschem (India) - Quaterly Results

05 Aug 2026 Evaluate
A slight decline in the revenue of Rs. 1259.48 millions was seen for the June 2026 quarter as against Rs. 1267.58 millions during year-ago period.The Net Loss for the quarter ended June 2026 is Rs. -16.68 millions as compared to Net Profit of Rs. 16.74 millions of corresponding quarter ended June 2025Operating profit for the quarter ended June 2026 decreased to 5.93 millions as compared to 24.70 millions of corresponding quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 1259.48 1267.58 -0.64 1259.48 1267.58 -0.64 6546.26 3862.31 69.49
Other Income 0.47 0.05 840.00 0.47 0.05 840.00 0.21 0.42 -50.00
PBIDT 5.93 24.70 -75.99 5.93 24.70 -75.99 211.13 40.24 424.68
Interest 4.90 0.39 1156.41 4.90 0.39 1156.41 22.64 0.66 3330.30
PBDT 1.03 24.31 -95.76 1.03 24.31 -95.76 188.49 39.58 376.23
Depreciation 15.55 7.57 105.42 15.55 7.57 105.42 40.63 29.47 37.87
PBT -14.52 16.74 -186.74 -14.52 16.74 -186.74 147.86 10.11 1362.51
TAX 2.16 0.00 0.00 2.16 0.00 0.00 38.58 5.52 598.91
Deferred Tax 2.16 0.00 0.00 2.16 0.00 0.00 38.58 5.52 598.91
PAT -16.68 16.74 -199.64 -16.68 16.74 -199.64 109.28 4.59 2280.83
Equity 536.16 435.13 23.22 536.16 435.13 23.22 490.13 435.13 12.64
PBIDTM(%) 0.47 1.95 -75.84 0.47 1.95 -75.84 3.23 1.04 209.55

Syschem (India) Share Price

34.80 0.62 (1.81%)
05-Aug-2026 09:55 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1939.60
Dr. Reddys Labs. 1163.60
Cipla 1450.30
Lupin 2371.70
Zydus Lifesciences 1113.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: